A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma

Rituximab in combination with chemotherapy has shown efficacy in patients with diffuse large B-cell lymphoma (DLBCL) for more than 15 years. HLX01 was developed as the rituximab biosimilar following a stepwise approach to demonstrate biosimilarity in analytical, pre-clinical, and clinical investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuankai, Song, Yongping, Qin, Yan, Zhang, Qingyuan, Han, Xiaohong, Hong, Xiaonan, Wang, Dong, Li, Wei, Zhang, Yang, Feng, Jifeng, Yang, Jianmin, Zhang, Huilai, Jin, Chuan, Yang, Yu, Hu, Jianda, Wang, Zhao, Jin, Zhengming, Su, Hang, Wang, Huaqing, Yang, Haiyan, Fu, Weijun, Zhang, Mingzhi, Zhang, Xiaohong, Chen, Yun, Ke, Xiaoyan, Liu, Li, Yu, Ding, Chen, Guo’an, Wang, Xiuli, Jin, Jie, Sun, Tao, Du, Xin, Cheng, Ying, Yi, Pingyong, Zhao, Xielan, Ma, Chaoming, Cheng, Jiancheng, Chai, Katherine, Luk, Alvin, Liu, Eugene, Zhang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164184/
https://www.ncbi.nlm.nih.gov/pubmed/32299513
http://dx.doi.org/10.1186/s13045-020-00871-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164184/
https://www.ncbi.nlm.nih.gov/pubmed/32299513
http://dx.doi.org/10.1186/s13045-020-00871-9

Ejemplares similares